IRIS Accounts Production v24.3.2.46 03584267 Board of Directors 1.4.23 31.3.24 31.3.24 true false true true false false false true false Fair value model Ordinary A 1.00000 Ordinary B 1.00000 Ordinary C 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh035842672023-03-31035842672024-03-31035842672023-04-012024-03-31035842672022-03-31035842672022-04-012023-03-31035842672023-03-3103584267ns15:EnglandWales2023-04-012024-03-3103584267ns14:PoundSterling2023-04-012024-03-3103584267ns10:Director12023-04-012024-03-3103584267ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3103584267ns10:FRS1022023-04-012024-03-3103584267ns10:Audited2023-04-012024-03-3103584267ns10:LargeMedium-sizedCompaniesRegimeForDirectorsReport2023-04-012024-03-3103584267ns10:LargeMedium-sizedCompaniesRegimeForAccounts2023-04-012024-03-3103584267ns10:FullAccounts2023-04-012024-03-310358426712023-04-012024-03-3103584267ns10:OrdinaryShareClass22023-04-012024-03-3103584267ns10:OrdinaryShareClass32023-04-012024-03-3103584267ns10:OrdinaryShareClass42023-04-012024-03-3103584267ns10:Director22023-04-012024-03-3103584267ns10:Director32023-04-012024-03-3103584267ns10:Director42023-04-012024-03-3103584267ns10:CompanySecretary12023-04-012024-03-3103584267ns10:RegisteredOffice2023-04-012024-03-310358426712023-04-012024-03-310358426712022-04-012023-03-3103584267ns5:CurrentFinancialInstruments2024-03-3103584267ns5:CurrentFinancialInstruments2023-03-3103584267ns5:ShareCapital2024-03-3103584267ns5:ShareCapital2023-03-3103584267ns5:RevaluationReserve2024-03-3103584267ns5:RevaluationReserve2023-03-3103584267ns5:RetainedEarningsAccumulatedLosses2024-03-3103584267ns5:RetainedEarningsAccumulatedLosses2023-03-3103584267ns5:ShareCapital2022-03-3103584267ns5:RetainedEarningsAccumulatedLosses2022-03-3103584267ns5:RevaluationReserve2022-03-3103584267ns5:RetainedEarningsAccumulatedLosses2022-04-012023-03-3103584267ns5:RevaluationReserve2022-04-012023-03-3103584267ns5:RetainedEarningsAccumulatedLosses2023-04-012024-03-3103584267ns5:RevaluationReserve2023-04-012024-03-3103584267ns5:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3103584267ns5:OwnedOrFreeholdAssetsns5:LandBuildings2023-04-012024-03-3103584267ns5:LongLeaseholdAssetsns5:LandBuildings2023-04-012024-03-3103584267ns5:FurnitureFittings2023-04-012024-03-3103584267ns5:MotorVehicles2023-04-012024-03-3103584267ns5:OwnedAssets2023-04-012024-03-3103584267ns5:OwnedAssets2022-04-012023-03-3103584267ns5:NetGoodwill2023-04-012024-03-3103584267ns5:NetGoodwill2022-04-012023-03-3103584267ns5:NetGoodwill2023-03-3103584267ns5:NetGoodwill2024-03-3103584267ns5:NetGoodwill2023-03-3103584267ns5:LandBuildings2023-03-3103584267ns5:LongLeaseholdAssetsns5:LandBuildings2023-03-3103584267ns5:FurnitureFittings2023-03-3103584267ns5:MotorVehicles2023-03-3103584267ns5:LandBuildings2023-04-012024-03-3103584267ns5:LandBuildings2024-03-3103584267ns5:LongLeaseholdAssetsns5:LandBuildings2024-03-3103584267ns5:FurnitureFittings2024-03-3103584267ns5:MotorVehicles2024-03-3103584267ns5:LandBuildings2023-03-3103584267ns5:LongLeaseholdAssetsns5:LandBuildings2023-03-3103584267ns5:FurnitureFittings2023-03-3103584267ns5:MotorVehicles2023-03-3103584267ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-03-3103584267ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-3103584267ns5:WithinOneYear2024-03-3103584267ns5:WithinOneYear2023-03-3103584267ns5:BetweenOneFiveYears2024-03-3103584267ns5:BetweenOneFiveYears2023-03-3103584267ns5:AllPeriods2024-03-3103584267ns5:AllPeriods2023-03-3103584267ns5:AcceleratedTaxDepreciationDeferredTax2024-03-3103584267ns5:AcceleratedTaxDepreciationDeferredTax2023-03-3103584267ns5:DeferredTaxation2023-03-3103584267ns5:DeferredTaxation2023-04-012024-03-3103584267ns5:DeferredTaxation2024-03-3103584267ns10:OrdinaryShareClass22024-03-3103584267ns10:OrdinaryShareClass32024-03-3103584267ns10:OrdinaryShareClass42024-03-31
REGISTERED NUMBER: 03584267 (England and Wales)















Strategic Report, Report of the Directors and

Financial Statements for the Year Ended 31 March 2024

for

Lo's Pharmacy Limited

Lo's Pharmacy Limited (Registered number: 03584267)






Contents of the Financial Statements
for the Year Ended 31 March 2024




Page

Company Information 1

Strategic Report 2

Report of the Directors 4

Independent Auditors' Report 6

Statement of Comprehensive Income 9

Balance Sheet 10

Statement of Changes in Equity 11

Cash Flow Statement 12

Notes to the Cash Flow Statement 13

Notes to the Financial Statements 14


Lo's Pharmacy Limited

Company Information
for the Year Ended 31 March 2024







DIRECTORS: Mr K K K Lo
Mr S K F Lo
Mr C G Lo
Mr J Lo





SECRETARY: Mr K K K Lo





REGISTERED OFFICE: Unit 5
Farfield Park
Manvers
Rotherham
South Yorkshire
S63 5DB





REGISTERED NUMBER: 03584267 (England and Wales)





AUDITORS: Harris & Co Limited
Chartered Accountants & Statutory Auditor
Marland House
13 Huddersfield Road
Barnsley
South Yorkshire
S70 2LW

Lo's Pharmacy Limited (Registered number: 03584267)

Strategic Report
for the Year Ended 31 March 2024

The directors present their strategic report for the year ended 31 March 2024.

PRINCIPAL RISKS AND UNCERTAINTIES
The company's operations expose it to a variety of financial risks that include the effects of price risk, credit risk, liquidity risk and interest rate risk. The company does not use derivative financial instruments to manage interest rate costs and as such no hedge accounting is applied.

The board of directors is responsible for monitoring financial risk and for deciding where it would be appropriate to use financial instruments to manage this risk.

Price risk
The company has no exposure to equity securities price risk as it holds no listed or other equity investments.

Credit risk
Other than the NHS Business Services Authority the company has no significant credit customers and is therefore not materially exposed to credit risk.

Liquidity risk
The company actively maintains a mixture of overdraft finance and lending from related companies that is designed to ensure the company has sufficient available funds for operations and planned expansions.

Interest rate risk
The company has both interest bearing assets and interest bearing liabilities. Interest bearing assets are cash and bank deposits which earn interest at a variable rate. Interest bearing liabilities include overdrafts and both short and long term debt. The board of directors regularly review the mix of overdraft and debt to manage interest risk and where possible use fixed rate debt to ensure certainty of future interest cash flows. The directors will revisit the appropriateness of this policy should the company's operations change in size or nature.

Other risks
The company operates in a highly regulated market and changes to those regulations, including changes to the NHS pharmacy contract, could potentially have a significant impact on the business. Management regularly review pending or potential changes to regulations and take steps to minimise the impact on the business.

BUSINESS REVIEW
The directors aim to present a balanced and comprehensive review of the development and performance of our business during the year and its position at the year-end. Our review is consistent with the size and non-complex nature of our business and is written in the context of the risks and uncertainties we face.

Turnover has increased by £111k to £7.29m (2023: increase of £206k to £7.18m) reflecting an increase in prescription prices and over the counter (OTC) sales. The gross profit margin increased to 31.4% (2023: 31.3%) and gross profit increased by £45k to £2.29m. Other operating income increased by £5k to £63k with profit before tax increasing to £283k (2023: £277k). After taxation, £229k has been retained to be added to reserves (2023: £197k), with no dividends being paid or proposed during the year (2023: £nil).

The company's shareholders' funds increased by £532k in the year to £8.46m (2023: £7.93m) reflecting a £303k increase in undistributable reserves, a result of a revaluation of investment property in the year, together with £229k retained profit. Net current assets increased by £243k to £6.58m (2023: £6.33m).

Based on the company's strong balance sheet, the company is well positioned to meet the principal risks and uncertainties detailed below. Accordingly, in the opinion of the directors, it is therefore appropriate to prepare the accounts on a going concern basis.


Lo's Pharmacy Limited (Registered number: 03584267)

Strategic Report
for the Year Ended 31 March 2024

KEY PERFORMANCE INDICATORS
We consider that our key financial performance indicators are those that communicate the financial performance of the group, these being turnover, operating profit, profits before taxation and EBITDA.

ON BEHALF OF THE BOARD:





Director


18 December 2024

Lo's Pharmacy Limited (Registered number: 03584267)

Report of the Directors
for the Year Ended 31 March 2024

The directors present their report with the financial statements of the Company for the year ended 31 March 2024.

PRINCIPAL ACTIVITY
The principal activity of the Company in the year under review was that of dispensing chemists.

DIVIDENDS
No dividends will be distributed for the year ended 31 March 2024.

DIRECTORS
The directors shown below have held office during the whole of the period from 1 April 2023 to the date of this report.

Mr K K K Lo
Mr S K F Lo
Mr C G Lo
Mr J Lo

DISCLOSURE IN THE STRATEGIC REPORT
The company has chosen in accordance with section 414C(11) of the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 to set out in the company's strategic report information required by schedule 7 of the Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008. This includes information that would have been included in the business review and the principal risks and uncertainties.

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing these financial statements, the directors are required to:

-select suitable accounting policies and then apply them consistently;
-make judgements and accounting estimates that are reasonable and prudent;
-prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the Company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the Company's auditors are aware of that information.

Lo's Pharmacy Limited (Registered number: 03584267)

Report of the Directors
for the Year Ended 31 March 2024


AUDITORS
The auditors, Harris & Co Limited, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:





Mr S K F Lo - Director


18 December 2024

Independent Auditors' Report to the Members of
Lo's Pharmacy Limited

Opinion
We have audited the financial statements of Lo's Pharmacy Limited (the 'Company') for the year ended 31 March 2024 which comprise the Statement of Comprehensive Income, Balance Sheet, Statement of Changes in Equity, Cash Flow Statement and Notes to the Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the Company's affairs as at 31 March 2024 and of its profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Auditors' Report thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Independent Auditors' Report to the Members of
Lo's Pharmacy Limited


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page four, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

Identifying and assessing potential risks related to irregularities
In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

- Enquiring of management, including obtaining and reviewing supporting documentation, concerning
the company's policies and procedures relating to:

-
Identifying, evaluating and complying with laws and regulations and whether they were aware of
any instances of non-compliance;

-
Detecting and responding to the risks of fraud and whether they have knowledge of any actual,
suspected or alleged fraud;

-
The internal controls established to mitigate risk related to fraud or non-compliance with laws &
regulations;
- Obtaining an understanding of the legal and regulatory frameworks that the company operates in,
focusing on those laws and regulations that had a direct effect on the financial statements or that had a
fundamental effect on the operations of the company. The key laws and regulations we considered in
this context included the UK Companies Act, tax legislation, data protection, anti bribery, employment
and health and safety regulations and the Medicine Act.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' Report.

Independent Auditors' Report to the Members of
Lo's Pharmacy Limited


Audit response to risks identified
Our procedures to respond to risks identified included the following:

- Reviewing the financial statement disclosures and testing to supporting documentation to assess
compliance with relevant laws and regulations;
- Enquiring of management concerning actual and potential litigation and claims;
- Performing analytical procedures to identify any unusual or unexpected relationships that may indicate
risk of material misstatement due to fraud; and
- In addressing the risk of fraud through management override of controls, testing the appropriateness
of journal entries and other adjustments; assessing the judgements used in accounting estimates to
assess whether these may be indicative of potential bias; and evaluating the business rationale of any
significant transactions that are unusual or outside the normal course of business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

Use of our report
This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Tom Garner CA CTA (Senior Statutory Auditor)
for and on behalf of Harris & Co Limited
Chartered Accountants & Statutory Auditor
Marland House
13 Huddersfield Road
Barnsley
South Yorkshire
S70 2LW

18 December 2024

Lo's Pharmacy Limited (Registered number: 03584267)

Statement of Comprehensive
Income
for the Year Ended 31 March 2024

2024 2023
Notes £    £   

TURNOVER 7,294,865 7,183,675

Cost of sales 5,004,035 4,937,777
GROSS PROFIT 2,290,830 2,245,898

Administrative expenses 2,068,454 2,024,909
222,376 220,989

Other operating income 4 62,763 57,937
OPERATING PROFIT 6 285,139 278,926


Interest payable and similar expenses 7 2,337 2,309
PROFIT BEFORE TAXATION 282,802 276,617

Tax on profit 8 53,727 79,165
PROFIT FOR THE FINANCIAL YEAR 229,075 197,452

OTHER COMPREHENSIVE INCOME
Revaluation of investment property 303,069 -
Income tax relating to other
comprehensive income

-

-
OTHER COMPREHENSIVE INCOME
FOR THE YEAR, NET OF INCOME TAX

303,069

-
TOTAL COMPREHENSIVE INCOME
FOR THE YEAR

532,144

197,452

Lo's Pharmacy Limited (Registered number: 03584267)

Balance Sheet
31 March 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 9 - -
Tangible assets 10 1,096,870 1,198,675
Investment property 11 810,000 445,000
1,906,870 1,643,675

CURRENT ASSETS
Stocks 12 280,956 321,896
Debtors 13 7,083,074 6,575,538
Cash at bank and in hand 15,596 178,152
7,379,626 7,075,586
CREDITORS
Amounts falling due within one year 14 804,330 743,776
NET CURRENT ASSETS 6,575,296 6,331,810
TOTAL ASSETS LESS CURRENT
LIABILITIES

8,482,166

7,975,485

PROVISIONS FOR LIABILITIES 17 18,235 43,698
NET ASSETS 8,463,931 7,931,787

CAPITAL AND RESERVES
Called up share capital 18 110,000 110,000
Undistributable reserves 318,069 15,000
Retained earnings 8,035,862 7,806,787
SHAREHOLDERS' FUNDS 8,463,931 7,931,787

The financial statements were approved by the Board of Directors and authorised for issue on 18 December 2024 and were signed on its behalf by:





Mr S K F Lo - Director


Lo's Pharmacy Limited (Registered number: 03584267)

Statement of Changes in Equity
for the Year Ended 31 March 2024

Called up
share Retained Undistributable Total
capital earnings reserves equity
£    £    £    £   
Balance at 1 April 2022 110,000 7,609,335 15,000 7,734,335

Changes in equity
Total comprehensive income - 197,452 - 197,452
Balance at 31 March 2023 110,000 7,806,787 15,000 7,931,787

Changes in equity
Total comprehensive income - 229,075 303,069 532,144
Balance at 31 March 2024 110,000 8,035,862 318,069 8,463,931

Lo's Pharmacy Limited (Registered number: 03584267)

Cash Flow Statement
for the Year Ended 31 March 2024

2024 2023
Notes £    £   
Cash flows from operating activities
Cash generated from operations 1 (142,478 ) 144,272
Interest paid (2,337 ) (2,309 )
Tax paid (76,674 ) (175,149 )
Net cash from operating activities (221,489 ) (33,186 )

Cash flows from investing activities
Purchase of tangible fixed assets (37,874 ) (13,243 )
Net cash from investing activities (37,874 ) (13,243 )

Cash flows from financing activities
Amount introduced by directors 326 465
Net cash from financing activities 326 465

Decrease in cash and cash equivalents (259,037 ) (45,964 )
Cash and cash equivalents at
beginning of year

2

178,152

224,116

Cash and cash equivalents at end of
year

2

(80,885

)

178,152

Lo's Pharmacy Limited (Registered number: 03584267)

Notes to the Cash Flow Statement
for the Year Ended 31 March 2024

1. RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM
OPERATIONS

2024 2023
£    £   
Profit before taxation 282,802 276,617
Depreciation charges 77,748 137,363
Finance costs 2,337 2,309
362,887 416,289
Decrease in stocks 40,940 16,760
Increase in trade and other debtors (507,536 ) (74,564 )
Decrease in trade and other creditors (38,769 ) (214,213 )
Cash generated from operations (142,478 ) 144,272

2. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

Year ended 31 March 2024
31/3/24 1/4/23
£    £   
Cash and cash equivalents 15,596 178,152
Bank overdrafts (96,481 ) -
(80,885 ) 178,152
Year ended 31 March 2023
31/3/23 1/4/22
£    £   
Cash and cash equivalents 178,152 224,116


3. ANALYSIS OF CHANGES IN NET FUNDS/(DEBT)

At 1/4/23 Cash flow At 31/3/24
£    £    £   
Net cash
Cash at bank and in hand 178,152 (162,556 ) 15,596
Bank overdrafts - (96,481 ) (96,481 )
178,152 (259,037 ) (80,885 )
Total 178,152 (259,037 ) (80,885 )

Lo's Pharmacy Limited (Registered number: 03584267)

Notes to the Financial Statements
for the Year Ended 31 March 2024

1. STATUTORY INFORMATION

Lo's Pharmacy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation and functional currency of the financial statements is the Pound Sterling (£).

2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

3. ACCOUNTING POLICIES

Company information and basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS102) and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.

The principal accounting policies and significant judgements and estimates applied in the preparation of these financial statements are set out below. These policies, judgements and estimates have been consistently applied to all years presented unless otherwise stated.

Going concern
Based on the company's strong balance sheet, the company is well positioned to meet the principal risks and uncertainties detailed in the strategic report. Accordingly, in the opinion of the directors, it is therefore appropriate to prepare the accounts on a going concern basis.

Significant judgements and estimates
No significant judgements or estimates have had to be made by management in preparing these financial statements other than as described in the following accounting policies.

Turnover
Turnover represents amounts earned on goods and services provided during the year and derives from the provision of goods and services falling within the company's ordinary activities. 100% of the company's turnover results from activities in the United Kingdom.

Pharmacy licences
Pharmacy licences are initially measured at cost. After initial recognition, pharmacy licence assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset. Pharmacy licence assets are tested for impairment when there is an indication that the carrying amount may not be recoverable.

Amortisation is calculated as follows:

Pharmacy licenses- straight line over 20 years

Lo's Pharmacy Limited (Registered number: 03584267)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

3. ACCOUNTING POLICIES - continued

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Freehold property - 5% on cost straight line and 2% on cost straight line
Long leasehold - Over the life of the lease straight line
Fixtures and fittings - 33% on reducing balance and 15% on reducing balance
Motor vehicles - 25% on reducing balance

All fixed assets are initially recorded at cost.

Investment property
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Cost is calculated using the first in, first out method.

Financial instruments
The company has adopted the provisions set out in sections 11 and 12 of FRS 102 in the recognition and measurement of financial instruments. All financial instruments are initially measured at the original transaction price, less associated costs. For subsequent measurement, basic financial instruments are measured at amortised cost in accordance with section 11 of FRS 102. Other financial instruments that are not considered basic and that are material to the financial statements are measured at fair value through profit or loss in accordance with section 12 of FRS 102.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Comprehensive Income, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Lo's Pharmacy Limited (Registered number: 03584267)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

4. OTHER OPERATING INCOME
2024 2023
£    £   
Rents received 62,763 57,937

5. EMPLOYEES AND DIRECTORS
2024 2023
£    £   
Wages and salaries 1,221,502 1,219,923
Social security costs 82,412 88,087
Other pension costs 52,219 51,148
1,356,133 1,359,158

The average number of employees during the year was as follows:
2024 2023

Administration staff 74 69

2024 2023
£    £   
Directors' remuneration 32,234 76,900
Directors' pension contributions to money purchase schemes 33,000 32,000

The number of directors to whom retirement benefits were accruing was as follows:

Money purchase schemes 4 5

6. OPERATING PROFIT

The operating profit is stated after charging:

2024 2023
£    £   
Depreciation - owned assets 77,748 58,839
Pharmacy licences amortisation - 78,524
Auditors remuneration - audit of the financial statements 11,350 9,250
Auditors remuneration - non audit work 1,500 1,250

7. INTEREST PAYABLE AND SIMILAR EXPENSES
2024 2023
£    £   
Bank interest 2,337 2,309

Lo's Pharmacy Limited (Registered number: 03584267)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

8. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
2024 2023
£    £   
Current tax:
UK corporation tax 79,190 78,818

Deferred tax (25,463 ) 347
Tax on profit 53,727 79,165

Reconciliation of total tax charge included in profit and loss
The tax assessed for the year is lower than the standard rate of corporation tax in the UK. The difference is explained below:

2024 2023
£    £   
Profit before tax 282,802 276,617
Profit multiplied by the standard rate of corporation tax in the UK of
25% (2023 - 19%)

70,701

52,557

Effects of:
Expenses not deductible for tax purposes 171 36
Depreciation in excess of capital allowances 9,426 25,307
Adjustments to tax charge in respect of previous periods (1,108 ) 918
Deferred tax (25,463 ) 347
Total tax charge 53,727 79,165

Tax effects relating to effects of other comprehensive income

2024
Gross Tax Net
£    £    £   
Revaluation of investment property 303,069 - 303,069

9. INTANGIBLE FIXED ASSETS
Pharmacy
licences
£   
COST
At 1 April 2023
and 31 March 2024 2,981,763
AMORTISATION
At 1 April 2023
and 31 March 2024 2,981,763
NET BOOK VALUE
At 31 March 2024 -
At 31 March 2023 -

Lo's Pharmacy Limited (Registered number: 03584267)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

10. TANGIBLE FIXED ASSETS
Fixtures
Freehold Long and Motor
property leasehold fittings vehicles Totals
£    £    £    £    £   
COST
At 1 April 2023 1,242,262 348,692 449,810 16,550 2,057,314
Additions - - 37,874 - 37,874
Reclassification/transfer (96,068 ) - (41,329 ) - (137,397 )
At 31 March 2024 1,146,194 348,692 446,355 16,550 1,957,791
DEPRECIATION
At 1 April 2023 323,842 149,617 380,697 4,483 858,639
Charge for year 35,870 23,137 15,724 3,017 77,748
Reclassification/transfer (45,140 ) - (30,326 ) - (75,466 )
At 31 March 2024 314,572 172,754 366,095 7,500 860,921
NET BOOK VALUE
At 31 March 2024 831,622 175,938 80,260 9,050 1,096,870
At 31 March 2023 918,420 199,075 69,113 12,067 1,198,675

11. INVESTMENT PROPERTY

The investment properties were valued at £810,000 on 7 August 2024 by Andrew Corbett, of Smiths Chartered Surveyors, an independent Chartered Surveyor and member of the Royal Institute of Chartered Surveyors, based on the value as a single transfer as an investment property with the assured shorthold tenancy agreements in place. The historical cost of the investment property is £792,988.

Fair value at 31 March 2024 is represented by:
£   
Valuation in 2024 810,000

12. STOCKS
2024 2023
£    £   
Finished goods 280,956 321,896

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 539,194 647,382
Other debtors 6,428,953 5,803,185
VAT 76,369 88,748
Prepayments and accrued income 38,558 36,223
7,083,074 6,575,538

Lo's Pharmacy Limited (Registered number: 03584267)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts (see note 15) 96,481 -
Trade creditors 536,619 580,087
Corporation tax 80,415 77,899
Social security and other taxes 21,206 20,770
Other creditors 34,892 34,770
Directors' current accounts 1,845 1,519
Accruals and deferred income 32,872 28,731
804,330 743,776

15. LOANS

An analysis of the maturity of loans is given below:

2024 2023
£    £   
Amounts falling due within one year or on demand:
Bank overdrafts 96,481 -

16. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2024 2023
£    £   
Within one year 86,306 38,828
Between one and five years 94,761 66,123
181,067 104,951

17. PROVISIONS FOR LIABILITIES
2024 2023
£    £   
Deferred tax
Accelerated capital allowances 18,235 43,698

Deferred
tax
£   
Balance at 1 April 2023 43,698
Credit to Statement of Comprehensive Income during year (25,463 )
Balance at 31 March 2024 18,235

Lo's Pharmacy Limited (Registered number: 03584267)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2024

18. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
55,000 Ordinary A £1 55,000 55,000
33,000 Ordinary B £1 33,000 33,000
22,000 Ordinary C £1 22,000 22,000
110,000 110,000

19. CONTINGENT LIABILITIES

The company has entered into a limited multilateral guarantee arrangement in respect of the bank borrowings of SKF. Lo (Chemists) Limited, a related party. At 31 March 2024 the company's liability under these arrangements was £13,320,858 (2023: £11,958,084).

20. RELATED PARTY DISCLOSURES

The company traded with an entity under common control, during the year. Lo's Pharmacy Limited sold goods and services amounting to £214,477 (2023: £110,646) and purchased goods and services amounting to £41,207 (2023: £36,433), from this entity. Included in other debtors are loan balances due to Lo's Pharmacy Limited of £6,222,347 (2023: £5,662,671), from this entity.

The company traded with entities over which the entity has control, joint control or significant influence, during the year. Lo's Pharmacy Limited sold goods and services amounting to £11,118 (2023: £nil) and purchased goods and services amounting to £610 (2023: £nil), from these entities. Included in other debtors are loan balances due to Lo's Pharmacy Limited of £201,989 (2023: £180,474), from these entities.

At the year end the directors were owed £1,845 by the company (2023: £1,519).

21. ULTIMATE CONTROLLING PARTY

The controlling party is Mr S K F Lo.